FDA U-Turn Spurs Deals
4:40–6:41 · 121s
Tyler explains the agency’s sudden reversal on rare-disease trial rules, and Matt details new guidance that instantly boosted valuations and ignited a buyout frenzy.
4:40–6:41 · 121s
Tyler explains the agency’s sudden reversal on rare-disease trial rules, and Matt details new guidance that instantly boosted valuations and ignited a buyout frenzy.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.